Pune, India -- (SBWIRE) -- 05/24/2019 -- According to a new report published by Reports Monitor titled, "phenylketonuria Market by treatment, route of administration and End-user: Global Opportunity Analysis and Industry Forecast, 2017–2025," the global phenylketonuria Market is projected to grow rapidly from 2017 to 2025. North America is expected to grow lucratively maintain leading position throughout the forecast period.
Phenylketonuria is the medical condition that causes the amino acid build-up of phenylalanine owing to the mutation in the PAH gene that is culpable for production of the enzyme called phenylalanine hydroxylase. The dearth of the enzyme or inadequacy reduces the breakdown & conversion of the phenylalanine into tyrosine that is needed to create neurotransmitters such as norepinephrine, epinephrine, and dopamine. This condition results in a gradual accumulation of the amino acid inducing phenylketonuria condition. The disease is hereditary and symptoms include mental disorder, intellectual defect, seizures and brain damage. Treatment measures include Lofenalac formulated consumption and low protein content diet.
Get a Sample PDF Report: https://goo.gl/vgHt1B
Growing number of congenital metabolic disease increased healthcare expenditure, and diagnostic technological development leads the market to grow massively. Moreover, a large number of clinical trials performed, the response of the population group and high amount of drugs in the pipeline along with supportive actions deployed by the government are the factors lifting the growth of the market. Notwithstanding, rigorous and austere guidelines followed by FDA and time required for the approval for a new product are likely to constrain the market growth in coming times.
Phenylketonuria being hereditary disease and having no permanent cure provides lucrative opportunities to the players to introduce abiding treatment options.
Key Questions Answered:
- What will the market size and the growth rate be in 2025?
- What are the key factors driving the global cervical cancer diagnostic testing market?
- Who are the key vendors in the global cervical cancer diagnostic testing market?
- What are the challenges to market growth?
- What is the trending factors influencing the market shares of the Americas, APAC, and EMEA?
View Full Report Description with TOC: https://goo.gl/jFRjzp
Key Players profiled in the market are: Nutricia, Abbott, American Gene TechnologiesInternational Inc., BioMarin Pharmaceutical Inc., Biomarin, Vitaflo, Daiichi Sankyo Company, Dimension Therapeutics, Inc., Codexis, Inc., Synthetic Biologics, Inc., SOM Innovation Biotech SL, Erytech Pharma SA
The report has been categorized in two distinctive sections, where the first category titled as Market Overview provides a holistic view of the market, key trends, drivers, challenges/restraints or opportunities with their current and expected impact on the overall industry sales.
Our analyst implement several qualitative tools such as Ansoff's Matrix, PESTEL analysis, Porter's five force analysis among other to interpret and represent key industry findings.
The second section of the study provides market size, estimates and forecast for key market segments and regional market. The final part of the report highlights key manufacturers/vendors operating in the associated market.
Some Points from TOC:
1. Introduction
1.1. Market Definition
1.2. Market Scope
2. Research Methodology
2.1. Primary Research
2.2. Secondary Sources
2.3. Assumptions & Exclusions
3. Market Overview
3.1. Research Report Segmentation & Scope
3.2. Key Market Trend Analysis
3.2.1. Market Drivers
3.2.2. Market Restraint/Challenges
3.2.3. Market Opportunities
3.3. Porter's Five Forces Analysis
3.4. Potential Venture Avenues
3.5. Market Share Analysis, 2016
4. Treatment Overview
4.1. Introduction
4.2. Market Size & Forecast, 2015 to 2025
4.2.1. Drugs
4.2.1.1. Kuvan
4.2.1.2. Biopten
4.2.1.3. Others
4.2.2. Supplements
4.2.3. others
Continued…
View Full Press Release: https://garnerinsights.com/press-release/Phenylketonuria-Market